Cyclacel to host conference call on Monday, December 7 to discuss new Phase 2 sapacitabine data to be presented at ASH

Berkeley Heights, NJ, December 1, 2009 – Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company") will host a conference call on Monday, December 7 featuring Hagop M. Kantarjian, M.D., Chairman and Professor, Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas. Dr. Kantarjian will review Phase 2 sapacitabine data in elderly patients with acute myeloid leukemia (AML) and older patients with myelodysplastic syndromes (MDS) to be reported at the meeting of the American Society of Hematology (ASH) on Saturday, December 5.

Call details:

When: 9:30 am Eastern, December 7, 2009
Conference Call ID: 44436396
U.S./Canada dial-in: (877) 493-9121
International dial-in: (973) 582-2750
U.S./Canada replay: (800) 642-1687
International replay: (706) 645-9291

Webcast: For the live and archived webcast, please visit the Corporate Presentations page on the Cyclacel website at www.cyclacel.com. The webcast will be archived for 90 days and the audio replay for 7 days.

ASH Presentations

New Phase 2 clinical trial results of sapacitabine for the treatment of AML and MDS will be presented at two poster presentations during the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans, LA, on Saturday, December 5, 2009. Presentation details are as follows:

```
Abstract:      1061
Title:         A Randomized Phase 2 Study of Sapacitabine, An Oral    Nucleoside Analogue, in Elderly Patients with AML Previously Untreated or in First Relapse
Date/Time:     Saturday, December 5, 2009, 5:30 PM – 7:30 PM Central Time
Session:       Acute Myeloid Leukemia - Therapy, excluding Transplantation Poster I
Poster board:  I-83

Abstract:      1758
Title:         A Randomized Phase 2 Study of Sapacitabine, An Oral Nucleoside Analogue, in Older Patients with Myelodysplastic Syndromes (MDS) Refractory to Hypomethylating Agents
Date/Time:     Saturday, December 5, 2009, 5:30 PM – 7:30 PM Central Time
Session:       Myelodysplastic Syndromes Poster I
Poster board:  I-780
```

The abstracts are available online at http://ash.confex.com/ash/2009/webprogram/start.html.

About sapacitabine

Sapacitabine, an orally available nucleoside analogue, is currently being evaluated in three Phase 2 trials in hematological and solid tumors. Sapacitabine acts through a dual mechanism, interfering with DNA synthesis by causing single-strand DNA breaks and inducing arrest of cell cycle progression mainly at G2/M-Phase. Both sapacitabine and CNDAC, its major metabolite, have demonstrated potent anti-tumor activity in preclinical studies.

Over 150 patients have received sapacitabine in Phase 2 studies in AML, MDS, advanced cutaneous T cell lymphoma or CTCL and non-small cell lung cancer or NSCLC. Sapacitabine has been administered to approximately 170 patients in four Phase 1 studies with both hematologic malignancies and solid tumors. In the solid tumor studies, 20 patients experienced prolonged stable disease and remained on study for four months or longer, five with NSCLC, one with small cell lung cancer, four with colorectal, two with bladder, two with gastrointestinal stromal tumors, two with ovarian, one with breast, one with renal, one with parotid and one with an unknown primary tumor. Sapacitabine is part of Cyclacel's pipeline of small molecule drugs designed to target and stop uncontrolled cell division.

About Cyclacel Pharmaceuticals, Inc.

Cyclacel is a diversified biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Sapacitabine, a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and lung cancer and in Phase 1 in combination with seliciclib. Seliciclib, a CDK (cyclin dependent kinase) inhibitor, is in Phase 2 for the treatment of lung and nasopharyngeal cancer. CYC116, an Aurora kinase and VEGFR2 inhibitor, is in Phase 1 in patients with solid tumors. Cyclacel's ALIGN Pharmaceuticals subsidiary markets directly in the U.S. Xclair® Cream for radiation dermatitis, Numoisyn® Liquid and Numoisyn® Lozenges for xerostomia. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a portfolio of commercial products and a development pipeline of novel drug candidates. Please visit www.cyclacel.com for additional information.

Risk factors

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety, and intended utilization of Cyclacel's product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, the risk that Cyclacel will not obtain approval to market its products, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. These factors and others are more fully discussed under "Risk Factors" in the Annual Report on Form 10-K for the year ended December 31, 2008, as supplemented by the interim quarterly reports, filed with the SEC.

Contacts for Cyclacel Pharmaceuticals, Inc.

Investors/Media:
Corey Sohmer , (908) 517-7330
csohmer@cyclacel.com